FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer-Reference-Cited by-同舟云学术

FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer

Published:2023-05-25 Issue:1 Volume:12 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Lu Lu¹²,Jiang Yi-Xin¹,Liu Xiao-Xia¹,Jin Jin-Mei¹,Gu Wen-Jie¹,Luan Xin¹,Guan Ying-Yun³,Zhang Li-Jun¹

Affiliation:

1. Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China

2. Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, China

3. Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Funder

the National Natural Science Foundation of China

Young Talent Lifting Project of China Association of Chinese Medicine

Shanghai Rising-Star Program

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2023.2217024

Reference44 articles.